建立国家基本药物制度是“新医改”的重点和难点之一。制度出台前,列入基本药物目录的数量、种类以及对制药企业的影响是人们最关注的问题。而后,随着各地实施方案的出台并推进试点,一些矛盾开始显现,越来越多的困惑出现在人们面前。 The establishment of a national essential drug system is one of the key and difficult points of “new medical reform.” Before the promulgation of the system, the number and type of essential drugs included in the list, as well as the impact on the pharmaceutical industry, were issues of most concern. Then, with the introduction of programs around the country and the promotion of pilot projects, some contradictions began to emerge and more and more confusion appeared in front of people.